{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:42:28Z","timestamp":1792978948178,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/136177\/2018"],"award-info":[{"award-number":["SFRH\/136177\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.apsb.2021.02.012","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T01:39:29Z","timestamp":1615685969000},"page":"925-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":280,"title":["Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in\u00a0vivo studies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-1271","authenticated-orcid":false,"given":"Cl\u00e1udia Pina","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-0522","authenticated-orcid":false,"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Sousa Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-0232","authenticated-orcid":false,"given":"Ana Catarina","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.02.012_bib1","series-title":"Nanopharmaceuticals","first-page":"175","article-title":"Chapter 9 - nose-to-brain drug delivery: an alternative approach for effective brain drug targeting","author":"Alexander","year":"2020"},{"key":"10.1016\/j.apsb.2021.02.012_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03602532.2020.1726942","article-title":"Lipid-based nanoformulations in the treatment of neurological disorders","volume":"52","author":"Pottoo","year":"2020","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.apsb.2021.02.012_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bbamem.2008.10.022","article-title":"The blood\u2012brain barrier in brain homeostasis and neurological diseases","volume":"1788","author":"Weiss","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2021.02.012_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","article-title":"Potential of solid lipid nanoparticles in brain targeting","volume":"127","author":"Kaur","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/molecules25081929","article-title":"Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders","volume":"25","author":"Islam","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2021.02.012_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2012brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/17425247.2016.1092519","article-title":"Brain\u2012blood ratio: implications in brain drug delivery","volume":"13","author":"Kulkarni","year":"2016","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drudis.2019.10.005","article-title":"Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook","volume":"25","author":"Sabir","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.02.012_bib11","first-page":"20","article-title":"Oral and intra-nasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: considering its advantages and disadvantages","volume":"15","author":"Alavian","year":"2020","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.apsb.2021.02.012_bib12","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/138161210791164108","article-title":"Potential of nanoparticulate drug delivery systems by intranasal administration","volume":"16","author":"Ali","year":"2010","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.apsb.2021.02.012_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.02.012_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib15","first-page":"2088","article-title":"Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting","volume":"46","author":"Selvaraj","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.apsb.2021.02.012_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2021.02.012_bib18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","article-title":"Formulation and device design to increase nose to brain drug delivery","volume":"35","author":"Warnken","year":"2016","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2021.02.012_bib20","unstructured":"Shahaf D, Hadash J, Inventors; SIPNOSE Ltd., assignee. Nasal delivery device. United States patent US9227031B2. 2016 Jan 5."},{"key":"10.1016\/j.apsb.2021.02.012_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.02.012_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath actuated device improves delivery to target sites beyond the nasal valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.apsb.2021.02.012_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.apsb.2021.02.012_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood\u2012brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijpharm.2018.07.014","article-title":"A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in\u00a0vivo evaluation","volume":"548","author":"Youssef","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib32","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.02.012_bib34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jps.20318","article-title":"Nasal drug administration: potential for targeted central nervous system delivery","volume":"94","author":"Graff","year":"2005","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-i to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2021.02.012_bib36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017018693","article-title":"Lipid nanoparticles for nasal\/intranasal drug delivery","volume":"34","author":"Cunha","year":"2017","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.apsb.2021.02.012_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C6NR07581A","article-title":"Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles","volume":"9","author":"Ahmad","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2021.02.012_bib40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib41","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.2174\/138161282343180215151302","article-title":"Editorial: applications of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): state of the art","volume":"23","author":"Silva","year":"2017","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.apsb.2021.02.012_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review","volume":"112","author":"Garc\u00eas","year":"2018","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2021.02.012_bib44","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.2174\/138161281941131219123329","article-title":"Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia","volume":"19","author":"Silva","year":"2013","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.apsb.2021.02.012_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2012.05.010","article-title":"Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded slns and nlcs?","volume":"47","author":"Das","year":"2012","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib47","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.drudis.2019.03.021","article-title":"Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges","volume":"24","author":"Karami","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.02.012_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11094-019-02017-9","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems","volume":"53","author":"Shirodkar","year":"2019","journal-title":"Pharm Chem J"},{"key":"10.1016\/j.apsb.2021.02.012_bib50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","article-title":"Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures","volume":"14","author":"Ragelle","year":"2017","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.02.012_bib51","doi-asserted-by":"crossref","first-page":"102206","DOI":"10.1016\/j.nano.2020.102206","article-title":"Using the quality by design (qbd) approach to optimize formulations of lipid nanoparticles and nanoemulsions: a review","volume":"28","author":"Cunha","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.02.012_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12070599","article-title":"Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters","volume":"12","author":"Cunha","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.02.012_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.02.012_bib54","first-page":"285","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2011.07.035","article-title":"Lipid nanoparticles for brain targeting I. Formulation optimization","volume":"419","author":"Blasi","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib56","series-title":"Drug targeting and stimuli sensitive drug delivery systems","first-page":"749","article-title":"Chapter 20 - lipid nanoparticles: In\u00a0vitro and in\u00a0vivo approaches in drug delivery and targeting","author":"Lu","year":"2018"},{"key":"10.1016\/j.apsb.2021.02.012_bib57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pharmaceutics12030288","article-title":"Nanostructured lipid carriers for delivery of chemotherapeutics: a review","volume":"12","author":"Haider","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.02.012_bib58","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/jemt.22436","article-title":"The nasal cavity of the sheep and its olfactory sensory epithelium","volume":"77","author":"Barrios","year":"2014","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.apsb.2021.02.012_bib59","first-page":"257","article-title":"Rabbit respiratory system: clinical anatomy, physiology and disease","volume":"14","author":"Johnson-Delaney","year":"2011","journal-title":"Vet Clin: Exot Anim Pract"},{"key":"10.1016\/j.apsb.2021.02.012_bib60","series-title":"Comparative anatomy and histology","first-page":"71","article-title":"6 - Nose, sinus, pharynx, and larynx","author":"Harkema","year":"2012"},{"key":"10.1016\/j.apsb.2021.02.012_bib61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/nnm-2017-0365","article-title":"Enhanced brain penetration of pretomanid by intranasal administration of an oil-in-water nanoemulsion","volume":"13","author":"Shobo","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.02.012_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10667857.2019.1674522","article-title":"Improved brain pharmacokinetics following intranasal administration of N,N,N-trimethyl chitosan tailored mucoadhesive NLCS","volume":"35","author":"Pardeshi","year":"2020","journal-title":"Mater Technol"},{"key":"10.1016\/j.apsb.2021.02.012_bib63","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/03639045.2019.1593439","article-title":"Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using box-behnken design","volume":"45","author":"Jojo","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib64","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10837450.2019.1631846","article-title":"Intranasal tadalafil nanoemulsions: formulation, characterization and pharmacodynamic evaluation","volume":"24","author":"Elbardisy","year":"2019","journal-title":"Pharmaceut Dev Technol"},{"key":"10.1016\/j.apsb.2021.02.012_bib65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","article-title":"A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates. Relevance to inhalation toxicology and human health risk assessment","volume":"153","author":"Chamanza","year":"2015","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.apsb.2021.02.012_bib66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1208\/s12248-015-9724-x","article-title":"Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans","volume":"17","author":"Ruigrok","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2021.02.012_bib67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery--possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.02.012_bib68","series-title":"A comprehensive and practical guide to clinical trials","first-page":"11","article-title":"Chapter 2\u2014clinical trial phases","author":"Wright","year":"2017"},{"key":"10.1016\/j.apsb.2021.02.012_bib69","series-title":"Pharmacognosy","first-page":"495","article-title":"Chapter 25\u2014pharmacokinetics","author":"Turfus","year":"2017"},{"key":"10.1016\/j.apsb.2021.02.012_bib70","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2021.02.012_bib71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/jpet.119.257113","article-title":"Pharmacokinetic and pharmacodynamic properties of drug delivery systems","volume":"370","author":"Glassman","year":"2019","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2021.02.012_bib72","series-title":"Drug development","article-title":"The role of Pharmacokinetics and pharmacodynamics in the development of biotech drugs","author":"Meibohm","year":"2006"},{"key":"10.1016\/j.apsb.2021.02.012_bib73","article-title":"UM. In situ and ex\u00a0vivo nasal models for preclinical drug development studies","volume":"vol. III","author":"Agu","year":"2008"},{"key":"10.1016\/j.apsb.2021.02.012_bib74","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1080\/21691401.2018.1489826","article-title":"Impact of ultrasonication techniques on the preparation of novel amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy","volume":"46","author":"Ahmad","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.apsb.2021.02.012_bib75","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/21691401.2017.1337024","article-title":"Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia","volume":"46","author":"Ahmad","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.apsb.2021.02.012_bib76","first-page":"1838","article-title":"Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by box\u2013behnken design, in\u00a0vitro and in\u00a0vivo evaluation","volume":"46","author":"Yasir","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.apsb.2021.02.012_bib77","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijbiomac.2017.11.031","article-title":"Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: pharmacokinetic and teratogenic assessment","volume":"108","author":"Singh","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.02.012_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib79","article-title":"Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil","volume":"12","author":"Rajput Apb","year":"2018","journal-title":"Asian J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jddst.2019.01.040","article-title":"Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in\u00a0vivo characterization","volume":"51","author":"Rajput","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2021.02.012_bib81","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: In\u00a0vitro and in\u00a0vivo studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for cns delivery: optimization and hematological toxicity studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2021.02.012_bib83","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic iron oxide-loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.02.012_bib84","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1208\/s12249-018-1142-9","article-title":"Intranasal surface-modified mosapride citrate-loaded nanostructured lipid carriers (MOS-SMNLCs) for treatment of reflux diseases: in vitro optimization, pharmacodynamics, and pharmacokinetic studies","volume":"19","author":"Hammad","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2021.02.012_bib85","doi-asserted-by":"crossref","first-page":"110446","DOI":"10.1016\/j.colsurfb.2019.110446","article-title":"Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice","volume":"183","author":"Du","year":"2019","journal-title":"Colloids Surf, B"},{"key":"10.1016\/j.apsb.2021.02.012_bib86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in\u00a0vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib87","doi-asserted-by":"crossref","first-page":"2382563","DOI":"10.1155\/2019\/2382563","article-title":"Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-ohda Parkinson's disease model","volume":"2019","author":"Gaba","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2021.02.012_bib88","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/rej.2017.2035","article-title":"Selegiline nanoformulation in attenuation of oxidative stress and upregulation of dopamine in the brain for the treatment of Parkinson's disease","volume":"21","author":"Kumar","year":"2018","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.apsb.2021.02.012_bib89","doi-asserted-by":"crossref","first-page":"104917","DOI":"10.1016\/j.chemphyslip.2020.104917","article-title":"Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with huntington's disease: pharmacokinetic and brain delivery study","volume":"230","author":"Arora","year":"2020","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.apsb.2021.02.012_bib90","doi-asserted-by":"crossref","first-page":"119486","DOI":"10.1016\/j.ijpharm.2020.119486","article-title":"Intranasal delivery of topiramate nanoemulsion: pharmacodynamic, pharmacokinetic and brain uptake studies","volume":"585","author":"Patel","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib91","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.2147\/IJN.S214657","article-title":"The optimization design of lactoferrin loaded hupa nanoemulsion for targeted drug transport via intranasal route","volume":"14","author":"Jiang","year":"2019","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.02.012_bib92","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0006-3223(95)00180-8","article-title":"Brain potential changes after intranasal vs. Intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans","volume":"39","author":"Pietrowsky","year":"1996","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.apsb.2021.02.012_bib93","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0895-7061(98)00095-8","article-title":"Intranasal angiotensin ii directly influences central nervous regulation of blood pressure","volume":"11","author":"Derad","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.apsb.2021.02.012_bib94","author":"Medicine USNLo"},{"key":"10.1016\/j.apsb.2021.02.012_bib95","author":"Medicine USNLo"},{"key":"10.1016\/j.apsb.2021.02.012_bib96","series-title":"Emerging nanotechnologies for diagnostics, drug delivery and medical devices","first-page":"291","article-title":"Chapter 12 - Solid lipid nanoparticles in drug delivery: opportunities and challenges","author":"Deshpande","year":"2017"},{"key":"10.1016\/j.apsb.2021.02.012_bib97","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.02.012_bib98","doi-asserted-by":"crossref","first-page":"2834941","DOI":"10.1155\/2019\/2834941","article-title":"Lipid nano- and microparticles: an overview of patent-related research","volume":"2019","author":"Battaglia","year":"2019","journal-title":"J Nanomater"},{"key":"10.1016\/j.apsb.2021.02.012_bib99","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.addr.2007.05.004","article-title":"Lipid nanoparticles: perspectives and challenges","volume":"59","author":"Gasco","year":"2007","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:45:47Z","timestamp":1761929147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2211383521000605"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.02.012","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in\u00a0vivo studies","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}